LL-37 research and evidence overview

"Is there evidence for LL-37?" splits into two questions with opposite answers. As a piece of human biology, LL-37 is extremely well studied—hundreds of papers across immunology, microbiology, and dermatology describe where it is expressed, what it binds, and how it modulates immune responses. As something a person injects, it has essentially no evidence: no completed efficacy trials of systemically administered LL-37, no approved indication, and no established dosing or safety profile in humans.

Confusing the first body of work for the second is the central error in how this peptide is marketed. A molecule your own neutrophils make is not thereby demonstrated safe or useful to add from outside.

LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans—a 37-residue amphipathic helical peptide cleaved from the hCAP18 precursor. A widely cited review in Biochimica et Biophysica Acta (PMID 16716248) consolidates the structural and functional evidence:

• It is expressed in epithelial cells of the skin, testis, gastrointestinal tract, and respiratory tract, and in monocytes, neutrophils, T cells, NK cells, and B cells.
• It shows broad-spectrum antimicrobial activity.
• Beyond killing microbes, it regulates the inflammatory response, chemoattracts cells of the adaptive immune system to wounds and infection sites, binds and neutralizes bacterial LPS, and promotes re-epithelialization and wound closure.

Those wound-healing and immunomodulatory functions are the source of most claims made for LL-37 products. They are accurate descriptions of what the endogenous peptide does in tissue. The same review is candid that the biophysical understanding of mammalian antimicrobial peptides was, at the time of writing, "still very limited"—the structural basis for the immunomodulatory effects was less settled than the effects themselves.

LL-37 is not a straightforwardly beneficial molecule, and its own literature says so. A Nature Medicine study of rosacea (PMID 17676051) found that people with the condition express abnormally high cathelicidin levels in facial skin, in differently processed forms than in healthy skin. Injecting those rosacea-associated cathelicidin peptides into mouse skin increased inflammation, and deleting the cathelicidin gene in mice blocked the inflammatory response—direct evidence that the peptide can drive disease rather than resolve it.

The pattern continues in current work: LL-37 is used experimentally to induce injury models, including an LL-37-induced model of interstitial cystitis (PMID 42062411). A peptide administered in one laboratory to cause bladder injury and sold in another as an anti-inflammatory is a compound whose net effect depends heavily on concentration, location, and processing.

Dose- and context-dependence in both directions is a recognized feature of host defense peptides, and it is the reason "LL-37 is anti-inflammatory" is an incomplete statement rather than a straightforwardly true one.

Development interest in cathelicidins is genuine and ongoing, mostly framed around antibiotic resistance, and reviews continue to describe therapeutic potential in intestinal disease and infection. But interest in a target is not evidence for a product. Formulation, stability, degradation by host proteases, and cytotoxicity to human cells at higher concentrations are recognized obstacles that have kept LL-37 and its analogues in preclinical and early development rather than in clinical practice.

As of now, nothing published supports claims about immune enhancement, infection clearance, or healing from injected LL-37 in people. The molecule is real and important; the product category has run ahead of the trials.